Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer

Journal of B.U.ON.

Volumn 13, Issue 4, 2008, Pages 505-511

  Popov, Ivan ^a   Radosevic Jelic, L ^a   Jezdic, S ^a   Milovic, M ^a   Borojevic, N ^a   Stojanovic, S ^a   Stankovic, V ^a   Josifovski, T ^a   Kezic, I ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Advanced disease; Cisplatin; Gastric cancer; Oxaliplatin; Randomized phase II study

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTE; HEART RHYTHM; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; SEPSIS; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS;

EID: 58149335121     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. McDonald JS, Cervantes A. New horizons for gastric cancer. Eur J Cancer 2006; 4(10 Suppl): 1-3.
2. Wagner AD, Grothe W, Hearting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909.
3. Kim DY, Kim JH, Lee SH et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 2003; 14: 383-387.
4. Louvet C, de Gramont A, Demuynck B et al. High-dose of folinic acid, 5-fluorouracil bolus and continuous infusion in poor prognosis patients with advanced measurable gastric cancer. Ann Oncol 1991; 2: 229-230.
5. Rubin J, Hallagher JG, Schroeder G et al. Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer 1996; 78: 1888-1891.
6. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997; 15: 808-815.
7. Lecomte TL, Mitry, E, Taieb J et al. Combination of 5-FU and cisplatin for metastatic pancreatic (P) and gastric (G) cancers: A randomized comparison of two regimens (LV5FU2-P vs FUP). Gut 2001; 49 (Suppl III): 2777.
8. Raymond E, Faivre S, Woynarowski JM et al. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25: 4-12.
9. Bleiberg H, de Gramont A. Oxaliplatin plus 5-fluorouracil. Semin Oncol 1998; 25: 32-39.
10. Raymond E, Chaney SC, Taamma A et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053-1071.
11. Becouarn Y, Agostini C, Trufflander N et al. Oxaliplatin: Available data in non-colorectal gastrointestinal malignancies. Crit Rev Oncol Hematol 2001; 40: 265-272.
12. Pascal A, Thierry A, Tigaud LM et al. Oxaliplatin, 5-fluorouracil, and folinic acid (FOLFOX6) in advanced/metastatic gastric carcinoma patients: final results of a multicenter phase II study. Proc Am Soc Clin Oncol 2001; 20: 654.
13. NCI-Common Toxicity Criteria, Version 2.0. National Cancer Institute, Division of Cancer Treatment, 1999.
14. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
15. Cunningham D, Rao S, Starling N et al. Randomized multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. J Clin Oncol 2006; 24 (Suppl 18): 182s (abstr LBA4017).
16. Van Cutsem E, Moiseyenko VM, Tjulandin S et al; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.
17. Ajani JA. The role of docetaxel in gastric cancer. Ear J Cancer 2006; 4(10 Suppl): 4-9.
18. Al-Batran SE, Atmaca A, Hegewich-Becker S et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22: 658-663.
19. Chao Y, Yeh KH, Chang CJ et al. Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 2004; 91: 453-458.
20. Cunningham D. Is oxaliplatin the optimal platinum agent in gastric cancer? Eur J Cancer 2006; 4(10 Suppl): 10-13.